APO RESEARCH · REPORT
Varicella Attenuated Live Vaccine
A live attenuated varicella vaccine, derived from the Oka strain of VZV has clinical efficacy for the prevention of varicella.
Product & engineering
Understand the product.
A live attenuated varicella vaccine, derived from the Oka strain of VZV has clinical efficacy for the prevention of varicella.
Selected research
Industry Research
Varicella Attenuated Live Vaccine Industry Research Report 2026
Market perspective
A live attenuated varicella vaccine, derived from the Oka strain of VZV has clinical efficacy for the prevention of varicella.
For the major players of Varicella Attenuated Live Vaccine, Merck maintained its first place in the ranking in 2019, followed by BCHT, Shanghai Institute, GSK and Keygen. Top 5 players accounted for about 95% of the Global Varicella Attenuated Live Vaccine revenue market share in 2019.
The sales market for Varicella Attenuated Live Vaccine was divided into five geographic regions. Asia-Pacific occupied the largest sales market share with about 58% in 2019. It is followed by North America and Europe with about 18% and about 13% respectively, while other regions have smaller market.
Read the full market overview
Report Scope
This report quantifies the global Varicella Attenuated Live Vaccine market in terms of revenue (US$ million) and, where applicable, sales volume (k doses), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k doses) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Varicella Attenuated Live Vaccine Market by Company
Merck
BCHT
Shanghai Institute
GSK
Keygen
Green Cross
Biken
Shanghai Rongsheng Biotech
Changchun Changsheng Life Sciences Limited
Varicella Attenuated Live Vaccine Segment by Type
Monovalent Vaccine
Combination Vaccine
Varicella Attenuated Live Vaccine Segment by Application
Kids Injection
Adults Injection
Varicella Attenuated Live Vaccine Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Varicella Attenuated Live Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Varicella Attenuated Live Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Varicella Attenuated Live Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Varicella Attenuated Live Vaccine manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Varicella Attenuated Live Vaccine by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Varicella Attenuated Live Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Monovalent Vaccine
- Combination Vaccine
Applications
- Kids Injection
- Adults Injection
Companies covered
- Merck
- BCHT
- Shanghai Institute
- GSK
- Keygen
- Green Cross
- Biken
- Shanghai Rongsheng Biotech
- Changchun Changsheng Life Sciences Limited
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Varicella Attenuated Live Vaccine Market Size (2021-2032)
- 2.2.2 Global Varicella Attenuated Live Vaccine Sales (2021-2032)
- 2.2.3 Global Varicella Attenuated Live Vaccine Market Average Price (2021-2032)
- 2.3 Varicella Attenuated Live Vaccine by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Monovalent Vaccine
- 2.3.3 Combination Vaccine
- 2.4 Varicella Attenuated Live Vaccine by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Kids Injection
- 2.4.3 Adults Injection
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Varicella Attenuated Live Vaccine Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Varicella Attenuated Live Vaccine Sales (k doses) of Manufacturers (2021-2026)
- 3.3 Global Varicella Attenuated Live Vaccine Revenue of Manufacturers (2021-2026)
- 3.4 Global Varicella Attenuated Live Vaccine Average Price by Manufacturers (2021-2026)
- 3.5 Global Varicella Attenuated Live Vaccine Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Varicella Attenuated Live Vaccine, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Varicella Attenuated Live Vaccine, Product Type & Application
- 3.8 Global Manufacturers of Varicella Attenuated Live Vaccine, Established Date
- 3.9 Global Varicella Attenuated Live Vaccine Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Merck
- 4.1.1 Merck Company Information
- 4.1.2 Merck Business Overview
- 4.1.3 Merck Varicella Attenuated Live Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Merck Varicella Attenuated Live Vaccine Product Portfolio
- 4.1.5 Merck Recent Developments
- 4.2 BCHT
- 4.2.1 BCHT Company Information
- 4.2.2 BCHT Business Overview
- 4.2.3 BCHT Varicella Attenuated Live Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 BCHT Varicella Attenuated Live Vaccine Product Portfolio
- 4.2.5 BCHT Recent Developments
- 4.3 Shanghai Institute
- 4.3.1 Shanghai Institute Company Information
- 4.3.2 Shanghai Institute Business Overview
- 4.3.3 Shanghai Institute Varicella Attenuated Live Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Shanghai Institute Varicella Attenuated Live Vaccine Product Portfolio
- 4.3.5 Shanghai Institute Recent Developments
- 4.4 GSK
- 4.4.1 GSK Company Information
- 4.4.2 GSK Business Overview
- 4.4.3 GSK Varicella Attenuated Live Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 GSK Varicella Attenuated Live Vaccine Product Portfolio
- 4.4.5 GSK Recent Developments
- 4.5 Keygen
- 4.5.1 Keygen Company Information
- 4.5.2 Keygen Business Overview
- 4.5.3 Keygen Varicella Attenuated Live Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Keygen Varicella Attenuated Live Vaccine Product Portfolio
- 4.5.5 Keygen Recent Developments
- 4.6 Green Cross
- 4.6.1 Green Cross Company Information
- 4.6.2 Green Cross Business Overview
- 4.6.3 Green Cross Varicella Attenuated Live Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Green Cross Varicella Attenuated Live Vaccine Product Portfolio
- 4.6.5 Green Cross Recent Developments
- 4.7 Biken
- 4.7.1 Biken Company Information
- 4.7.2 Biken Business Overview
- 4.7.3 Biken Varicella Attenuated Live Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Biken Varicella Attenuated Live Vaccine Product Portfolio
- 4.7.5 Biken Recent Developments
- 4.8 Shanghai Rongsheng Biotech
- 4.8.1 Shanghai Rongsheng Biotech Company Information
- 4.8.2 Shanghai Rongsheng Biotech Business Overview
- 4.8.3 Shanghai Rongsheng Biotech Varicella Attenuated Live Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Shanghai Rongsheng Biotech Varicella Attenuated Live Vaccine Product Portfolio
- 4.8.5 Shanghai Rongsheng Biotech Recent Developments
- 4.9 Changchun Changsheng Life Sciences Limited
- 4.9.1 Changchun Changsheng Life Sciences Limited Company Information
- 4.9.2 Changchun Changsheng Life Sciences Limited Business Overview
- 4.9.3 Changchun Changsheng Life Sciences Limited Varicella Attenuated Live Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Changchun Changsheng Life Sciences Limited Varicella Attenuated Live Vaccine Product Portfolio
- 4.9.5 Changchun Changsheng Life Sciences Limited Recent Developments
5 Global Varicella Attenuated Live Vaccine Market Scenario by Region
- 5.1 Global Varicella Attenuated Live Vaccine Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Varicella Attenuated Live Vaccine Sales by Region: 2021-2032
- 5.2.1 Global Varicella Attenuated Live Vaccine Sales by Region: 2021-2026
- 5.2.2 Global Varicella Attenuated Live Vaccine Sales by Region: 2027-2032
- 5.3 Global Varicella Attenuated Live Vaccine Revenue by Region: 2021-2032
- 5.3.1 Global Varicella Attenuated Live Vaccine Revenue by Region: 2021-2026
- 5.3.2 Global Varicella Attenuated Live Vaccine Revenue by Region: 2027-2032
- 5.4 North America Varicella Attenuated Live Vaccine Market Facts & Figures by Country
- 5.4.1 North America Varicella Attenuated Live Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Varicella Attenuated Live Vaccine Sales by Country (2021-2032)
- 5.4.3 North America Varicella Attenuated Live Vaccine Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Varicella Attenuated Live Vaccine Market Facts & Figures by Country
- 5.5.1 Europe Varicella Attenuated Live Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Varicella Attenuated Live Vaccine Sales by Country (2021-2032)
- 5.5.3 Europe Varicella Attenuated Live Vaccine Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Varicella Attenuated Live Vaccine Market Facts & Figures by Country
- 5.6.1 Asia Pacific Varicella Attenuated Live Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Varicella Attenuated Live Vaccine Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Varicella Attenuated Live Vaccine Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Varicella Attenuated Live Vaccine Market Facts & Figures by Country
- 5.7.1 South America Varicella Attenuated Live Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Varicella Attenuated Live Vaccine Sales by Country (2021-2032)
- 5.7.3 South America Varicella Attenuated Live Vaccine Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Varicella Attenuated Live Vaccine Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Varicella Attenuated Live Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Varicella Attenuated Live Vaccine Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Varicella Attenuated Live Vaccine Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Varicella Attenuated Live Vaccine Sales by Type (2021-2032)
- 6.1.1 Global Varicella Attenuated Live Vaccine Sales by Type (2021-2032) & (k doses)
- 6.1.2 Global Varicella Attenuated Live Vaccine Sales Market Share by Type (2021-2032)
- 6.2 Global Varicella Attenuated Live Vaccine Revenue by Type (2021-2032)
- 6.2.1 Global Varicella Attenuated Live Vaccine Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Varicella Attenuated Live Vaccine Revenue Market Share by Type (2021-2032)
- 6.3 Global Varicella Attenuated Live Vaccine Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Varicella Attenuated Live Vaccine Sales by Application (2021-2032)
- 7.1.1 Global Varicella Attenuated Live Vaccine Sales by Application (2021-2032) & (k doses)
- 7.1.2 Global Varicella Attenuated Live Vaccine Sales Market Share by Application (2021-2032)
- 7.2 Global Varicella Attenuated Live Vaccine Revenue by Application (2021-2032)
- 7.2.1 Global Varicella Attenuated Live Vaccine Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Varicella Attenuated Live Vaccine Revenue Market Share by Application (2021-2032)
- 7.3 Global Varicella Attenuated Live Vaccine Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Varicella Attenuated Live Vaccine Value Chain Analysis
- 8.1.1 Varicella Attenuated Live Vaccine Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Varicella Attenuated Live Vaccine Production Mode & Process
- 8.2 Varicella Attenuated Live Vaccine Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Varicella Attenuated Live Vaccine Distributors
- 8.2.3 Varicella Attenuated Live Vaccine Customers
9 Global Varicella Attenuated Live Vaccine Analyzing Market Dynamics
- 9.1 Varicella Attenuated Live Vaccine Industry Trends
- 9.2 Varicella Attenuated Live Vaccine Industry Drivers
- 9.3 Varicella Attenuated Live Vaccine Industry Opportunities and Challenges
- 9.4 Varicella Attenuated Live Vaccine Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst